Pseudorheumatoid Dysplasia

LIke ThisLIke ThisLIke ThisLIke ThisLIke This

Progressive pseudorheumatoid dysplasia is an autosomal recessive disorder that affects joints. Young children with PPD may appear less active and more prone to joint aches and pains than their peers. Often, the first sign of PPD occurring during mid-childhood is enlargement of the finger joints. This swelling may be mistaken for juvenile rheumatoid arthritis, but it can be distinguished from JRA by X-rays and laboratory studies. Patients with PPD have bony enlargement of the finger joints without evidence of inflammation. As children with PPD become older, they develop skeletal changes that resemble common osteoarthritis and their joints can become quite painful. Many teenagers and young adults with PPD have benefited from joint replacement surgery, which improves their pain and increases their mobility.

Most, if not all, patients with PPD have mutations in the gene WISP3. We first reported the identification of disease causing mutations in this gene in 1999.

Although we have found WISP3 mutations in a large number of patients with PPD, we were surprised to discover that mice lacking this gene do not develop PPD. We are still trying to understand why and how WISP3 protects joints and cartilage in humans, and is unnecessary in mice.

We have established an international consortium of patients, clinicians and basic scientists to study PPD. The goals of this consortium are to improve the diagnosis and treatment for persons affected with PPD.

Pooling resources and sharing ideas is important for advancing our knowledge about PPD, since we estimate that only 7000 persons in the entire world are affected with this rare disease.

Among the questions we want to answer are:

  1. Are mutations in WISP3 the only cause of PPD?
  2. How does WISP3 function in human cartilage to protect against osteoarthritis?
  3. Why is WISP3 essential for human cartilage, but not for mouse cartilage?
  4. Can other organisms, such as zebrafish and fruitfly teach us about the biologic pathway in which WISP3 participates?

Interested in participating?

We welcome individuals and families who are affected by PPD to participate in our research by contacting us.

To better understand how WISP3 functions within the body, we are seeking joint material that is recovered from patients with PPD at the time of a diagnostic or medically-indicated procedure.

Studying the consequences of PPD at the cellular, biophysical, and protein levels may help in furthering the development of new therapeutic strategies.

Physicians seeking assistance in making a diagnosis of PPD are also welcome to contact us.

Request an Appointment

If this is a medical emergency, please dial 9-1-1. This form should not be used in an emergency.

Patient Information
Date of Birth:
Contact Information
Appointment Details
Send RequestIf you do not see the specialty you are looking for, please call us at: 617-355-6000.International visitors should call International Health Services at +1-617-355-5209.
Please complete all required fields

This department is currently not accepting appointment requests online. Please call us at: 617-355-6000. International +1-617-355-6000.

This department is currently not accepting appointment requests online. Please call us at: 617-355-6000. International +1-617-355-6000.

Thank you.

Your request has been successfully submitted

You will be contacted within 1 business day.

If you have questions or would like more information, please call:

617-355-6000 +1-617-355-6000
close
Find a Doctor
Search by Clinician's Last Name or Specialty:
Select by Location:
Search by First Letter of Clinician's Last Name: *ABCDEFGHIJKLMNOPQRSTUVWXYZ
BrowseSearch
Condition & Treatments
Search for a Condition or Treatment:
Show Items Starting With: *ABCDEFGHIJKLMNOPQRSTUVWXYZ
View allSearch
Locations
The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”
- Sandra L. Fenwick, President and CEO
Close